Posts by Former NIMH Director Thomas Insel about Clinical Research and Trials

Results from a major NIMH project provide evidence that coordinated specialty care can improve outcomes for first episode psychosis. Dr. Insel blogs about the RAISE project and other recent studies of coordinated care.

Tech companies are bringing their ability to extract knowledge from data to health care. Dr. Insel gives some examples that show the potential of new tech-based approaches to diagnosis and treatment.

Despite its reputation as a month for slowing down, August is busy at NIMH as the end of the fiscal year approaches. Dr. Insel takes time out to give an update on NIMH-supported clinical trials.

Dr. Insel discusses how the Precision Medicine Initiative will create a new kind of patient-driven research, which is similar to how innovative companies have created a new share economy based on trust.

Drug testing in mice has been a poor guide to effectiveness in humans; Dr. Insel talks about the need for research approaches that can more reliably guide medication development.

Dr. Insel discusses the importance of data sharing within the scientific community and highlights how NIMH is encouraging this process.

Dr. Insel talks about just published findings coming out of Army STARRS, a joint Army-NIMH effort to understand risk factors for suicide in the military.

NIMH is changing how it will support clinical trials. Dr. Insel summarizes the changes and the reasons behind them.

Dr. Insel talks about how NIMH’s RAISE study is exploring an integrated, multi-component approach to health care for schizophrenia.

Dr. Insel introduces an innovative approach that one group is taking to speed up the dissemination of research results into clinical practice.

Dr. Insel describes a new behavioral treatment for a neurologically based disorder that has traditionally been difficult to treat. 

Dr. Insel discusses the crisis of medication development for mental disorders.

Presentations at a recent meeting in San Diego showed how new technologies are being used to change the culture of science, empowering patients, and fueling innovative research approaches.

While fewer medical students are choosing psychiatry in the U.K., in the U.S. psychiatry is attracting increasing numbers of elite MD-PhD students who want to do research. These young scientists are committed to developing a new scientific basis for clinical care.

Dr. Insel discusses opportunities for treatment development.

Dr. Insel shares NIMH’s Top 10 Research Advances for 2011.

Dr. Insel discusses opportunities for treatment development.

Dr. Insel discusses the state of psychiatric research and development (R&D) in the public and private sectors

Dr. Insel discusses the complicated nature of research on the efficacy antidepressants.

Dr. Insel reflects on an exciting neuroscience conference where an increasing interest in neuropsychiatric disorders was evident.

Dr. Insel provides a vision for future clinical research.

Dr. Insel discusses the evolution of clinical research and changing priorities in clinical research funding.

Increasing evidence linking strep infection to OCD in children suggests that microbiomics may prove an important research area for understanding and treating mental disorders.

Dr. insel discusses two important initiatives that will have a broad impact on NIMH’s clinical research portfolio.